Related Experiment Videos
Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas
1Department of Pathology (Neuropathology), Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Abstract:
The vast majority of glioblastomas have CDKN2A, CDK4, or RB gene alterations that perturb the p16-cdk4-pRb cell cycle regulatory cascade. To explore whether immunohistochemical methods provide an alternative means of assessing this pathway, we studied 25 glioblastomas using a combination of molecular genetic and immunohistochemical assays. Homozygous deletion of the CDKN2A gene was detected in 12 of 25 (48%) cases, CDK4 amplification in 4 of 25 (16%) tumors, and loss of heterozygosity at the RB gene in 8 of 22 (36%) informative cases. Five of 25 (20%) glioblastomas had diffuse p16 immunohistochemical positivity. Significantly, all of these had either CDK4 amplification or RB LOH, suggesting that p16 immunopositivity only occurs in those tumors with alterations of another component in the pathway. Nineteen (76%) cases were uniformly immunonegative for p16, and 12 (48%) had CDKN2A homozygous deletions, but the remaining 7 cases lacked CDKN2A deletions, mutations and promoter methylation. All glioblastomas stained diffusely for cdk4, irrespective of CDK4 gene amplification status. Extensive pRb staining was present in most cases that maintained both RB alleles, and absent in most cases with RB loss, but there were notable discrepancies. Thus, p16 and pRb immunohistochemistry cannot replace molecular genetic analysis of this critical regulatory cascade; instead, the combined results hint at complex regulation of this cell cycle checkpoint. From a practical point of view, although p16 immunonegativity does not necessarily indicate CDKN2A deletion, diffuse positive p16 immunostaining strongly suggests either CDK4 amplification or RB loss and excludes CDKN2A deletion.
Insights
Glioblastomas often have cell cycle gene alterations. While p16 and pRb immunohistochemistry show promise, they cannot fully replace genetic analysis for assessing this critical pathway in glioblastoma.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Glioblastomas frequently exhibit alterations in CDKN2A, CDK4, or RB genes, disrupting the p16-cdk4-pRb cell cycle regulatory cascade.
- Investigating immunohistochemical methods as alternatives to molecular assays for assessing this pathway is crucial for glioblastoma research.
Purpose of the Study:
- To evaluate the utility of immunohistochemical methods for assessing the p16-cdk4-pRb cell cycle pathway in glioblastoma.
- To correlate immunohistochemical findings with molecular genetic alterations in glioblastoma.
Main Methods:
- Studied 25 glioblastomas using combined molecular genetic and immunohistochemical assays.
- Assessed CDKN2A gene status (homozygous deletion), CDK4 gene status (amplification), and RB gene status (loss of heterozygosity).
- Utilized immunohistochemistry for p16 and pRb protein expression.
Main Results:
- CDKN2A homozygous deletion in 48%, CDK4 amplification in 16%, and RB loss of heterozygosity in 36% of glioblastomas.
- Diffuse p16 immunopositivity (20%) correlated with CDK4 amplification or RB loss, excluding CDKN2A deletion.
- p16 immunonegativity did not always indicate CDKN2A deletion, and pRb staining showed discrepancies with RB allelic status.
Conclusions:
- Immunohistochemistry for p16 and pRb cannot fully replace molecular genetic analysis for the p16-cdk4-pRb pathway in glioblastoma.
- Combined molecular and immunohistochemical data suggest complex regulation of the cell cycle checkpoint in glioblastoma.
- Diffuse p16 immunostaining is a strong indicator of CDK4 amplification or RB loss, while p16 immunonegativity requires further genetic investigation.